NASDAQ: MRTX - Mirati Therapeutics, Inc.

Yield per half year: 0%
Sector: Healthcare

Share chart Mirati Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Mirati Therapeutics, Inc., онкологическая компания на клинической стадии, разрабатывает продукты-кандидаты для лечения генетических и иммунологических промоторов рака в Соединенных Штатах.

more details
Компания разрабатывает MRTX849, ингибитор KRAS G12C, который проходит фазу I / II клинических испытаний для лечения немелкоклеточного рака легкого (NSCL), колоректального рака, рака поджелудочной железы и других видов рака; и ситраватиниб, исследуемый спектрально-селективный ингибитор киназы, который находится в фазе II клинических испытаний для лечения рака NSCL, а также программа ингибиторов KRAS G12D, которая находится в стадии доклинической разработки. У него есть соглашение о сотрудничестве и лицензионное соглашение с BeiGene, Ltd. на разработку, производство и коммерциализацию ситраватиниба; и соглашение о клиническом сотрудничестве с Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. была основана в 1995 году, ее штаб-квартира находится в Сан-Диего, Калифорния.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2004-06-29
ISIN US60468T1051
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт http://www.mirati.com
Цена ао 58.7
Change price per day: 0% (58.7)
Change price per week: 0% (58.7)
Change price per month: 0% (58.7)
Change price per 3 month: 0% (58.7)
Change price per half year: 0% (58.7)
Change price per year: -0.9784% (59.28)
Change price per 3 year: -48.53% (114.04)
Change price per 5 year: -39.52% (97.05)
Change price per 10 year: 0% (58.7)
Change price per year to date: 0% (58.7)
All parameters

Underestimation

Title Value Grade
P/S 192.63 1
P/BV 2.4 6
P/E 0 0
EV/EBITDA -2.91 0
Total: 3.5

Efficiency

Title Value Grade
ROA, % -53.08 0
ROE, % -61.91 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0678 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 293.33 10
Yield Ebitda, % 249.16 10
Yield EPS, % 110.19 10
Total: 10
More

Transaction date Date of disclosure Insider Type Price Volume Quantity Share before, % Share after, % Document
02.06.2023 02.06.2023 Stelzer Laurie
Chief Financial Officer		 Sale 37.06 172 218 4647 0 -0.01 link
28.11.2022 28.11.2022 BAUM CHARLES M
President,Founder,Head of R&D		 Sale 100 6 925 600 69256 0 -0.13 link
28.11.2022 28.11.2022 BAUM CHARLES M
President,Founder,Head of R&D		 Purchase 17.41 1 205 750 69256 0 0.13 link
07.01.2022 07.01.2022 REED VICKIE S
SVP, Chief Accounting Officer		 Sale 135.94 46 899 345 0 0 link
07.01.2022 07.01.2022 Hickey Benjamin
EVP, Chief Commercial Officer		 Sale 135.94 266 986 1964 0 0 link
03.12.2021 03.12.2021 BAUM CHARLES M
President & Head of R&D		 Sale 133.2 6 287 570 47204 0 -0.09 link
03.12.2021 03.12.2021 BAUM CHARLES M
President & Head of R&D		 Purchase 8.49 400 762 47204 0 0.09 link

Institutions Volume Share, %
RTW Investments LP 6768514 9.65
Avoro Capital Advisors LLC 6666666 9.5
EcoR1 Capital, LLC 5748399 8.19
Vanguard Group Inc 5699632 8.13
Blackrock Inc. 3544311 5.05
Wellington Management Group, LLP 3319922 4.73
Boxer Capital, LLC 3201440 4.56
Aviva Holdings Ltd. 3135966 4.47
State Street Corporation 2745968 3.91
Morgan Stanley 2462132 3.51

ETF Share, % Profitability for 1 year, % Dividends, %
AdvisorShares Alpha DNA Equity Sentiment ETF 1.26 0
ProShares UltraShort Nasdaq Biotechnology 0.46 -40.36 1.76
JPMorgan BetaBuilders U.S. Small Cap Equity Fund 0.00512 24.75 1.59225
Nuveen ESG Small-Cap ETF 0.00157 13.91 1.41019
Dimensional U.S. Core Equity 2 ETF 0.00074 30.76 1.47098
Dimensional US Core Equity Market ETF 0.00032 30.98 1.40618
Columbia Research Enhanced Value ETF 0.00006 28.02 2.60097
Columbia Research Enhanced Core ETF 0.00002 33.58 1.60295



Head Job title Payment Year of birth
Dr. Charles M. Baum M.D., Ph.D. Founder, President, CEO & Director 1.07M 1958 (67 years)
Dr. James G. Christensen Ph.D. Executive VP & Chief Scientific Officer 1.76M 1968 (57 years)
Dr. Kelly Covello Ph.D. VP & Head of Medical Affairs N/A
Mr. Benjamin J. Hickey M.B.A. Chief Commercial Officer 769.03k 1975 (50 years)
Mr. Michael E. Paolucci Chief People Officer N/A 1960 (65 years)
Dr. Alan Bart Sandler M.D. Executive VP & Chief Medical Officer 591k 1957 (68 years)
Mr. John B. Moriarty Jr., J.D. Chief Legal Officer & Corporate Secretary N/A 1968 (57 years)
Mr. Aaron Ondrey Chief Financial Officer N/A 1976 (49 years)
Ms. Betsy Gelfand CPA Chief Accounting Officer, Principal Accounting Officer & VP of Finance N/A
Mr. Peter Lee Chief Compliance Officer N/A

Address: United States, San Diego, CA , 3545 Cray Court - open in Google maps, open in Yandex maps
Website: http://www.mirati.com